Supring, Ernie A.
HRN: 09-61-89 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/08/2025
CEFTRIAXONE 1G (VIAL)
01/08/2025
01/15/2025
IV
2g
OD
Eviscerated Bowels
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes